Justine Berthet

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 3

Top Topics

Tyrosine Kinase

Regulatory T Cells

Top Venues

Science translational medicine

Science immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Aurélien Voissière, Carlos Alberto Gomez Roca, Sylvie Chabaud, Céline Rodriguez, Axelle Nkodia, Justine Berthet, Laure Montane, Anne-Sophie Bidaux, Isabelle Treilleux, Lauriane Eberst, Catherine Terret, Iphigénie Korakis, Gwenaelle Garin, David Pérol, Jean-Pierre Delord, Christophe Caux, Bertrand Dubois, Christine Ménétrier-Caux, Nathalie Bendriss-Vermare, Philippe Alexandre Cassier
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers. Science translational medicine 16 (731) (2024)
Aurélien Voissière, Carlos Alberto Gomez Roca, Sylvie Chabaud, Céline Rodriguez, Axelle Nkodia, Justine Berthet, Laure Montane, Anne-Sophie Bidaux, Isabelle Treilleux, Lauriane Eberst, Catherine Terret, Iphigénie Korakis, Gwenaelle Garin, David Pérol, Jean-Pierre Delord, Christophe Caux, Bertrand Dubois, Christine Ménétrier-Caux, Nathalie Bendriss-Vermare, Philippe Alexandre Cassier
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers. Science translational medicine 16 (731) (2024)
Margaux Hubert, Elisa Gobbini, Coline Agnes Couillault, Thien-Phong Vu Manh, Anne-Claire Doffin, Justine Berthet, Céline Rodriguez, Vincent Ollion, Janice Kielbassa, Christophe Sajous, Isabelle Treilleux, Olivier Trédan, Bertrand Dubois, Marc Dalod, Nathalie Bendriss-Vermare, Christophe Caux, Jenny Valladeau-Guilemond
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. Science immunology 5 (46) (2020)